ICD Benefits Roughly Equal For Ischemics, Non-Ischemics – JAMA Study
This article was originally published in The Gray Sheet
Implantable cardioverter defibrillators are associated with roughly the same relative benefit over medical therapy in both non-ischemic and ischemic cardiomyopathy patients, according to a meta-analysis by Akshay Desai, MD, Brigham and Women's Hospital, et al.
You may also be interested in...
America's Health Insurance Plans' efforts to dissuade CMS from expanding ICD national coverage until more conclusive evidence becomes available reflects the insurance industry's insistence on evidence-based medicine to justify expensive technologies
Public Company Edition: Lixte’s small uplisting was the only biopharma initial public offering in the US during Thanksgiving week, but IPOs are ramping up again. Also, LifeSci launched its second SPAC and in follow-on offerings Reata brought in $281m and Intellia grossed $175m.
Orladeyo is the first oral prophylactic approved in the US for hereditary angioedema, with Japan and EU approvals expected to follow. Pricing of $485,000 a year undercuts segment leader.